Skip to main content

Peter Thiel-backed psychedelic start-up's shares pop in Wall Street debut

The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.